menu
    • menu
    [{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceutical"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Fresh Tracks Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"JAPAN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sofpironium Bromide","moa":"M3 receptor","graph1":"Dermatology","graph2":"Approved","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical gel","sponsorNew":"Kaken Pharmaceuticals \/ Brickell Biotech","highestDevelopmentStatusID":"12","companyTruncated":"Kaken Pharmaceuticals \/ Brickell Biotech"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Numab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"NM26-2198","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Kaken Pharmaceuticals \/ Kaken","highestDevelopmentStatusID":"6","companyTruncated":"Kaken Pharmaceuticals \/ Kaken"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Spruce Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Tildacerfont","moa":"","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"CymaBay Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Seladelpar Lysine","moa":"","graph1":"Hepatology (Liver, Pancreatic, Gall Bladder)","graph2":"Phase III","graph3":"Kaken Pharmaceuticals","amount2":0.16,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hepatology","amount2New":0.16,"dosageForm":"Capsule","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"bitBiome","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"JAPAN","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Numab Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SWITZERLAND","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"NM26-2198","moa":"","graph1":"Dermatology","graph2":"Phase I","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Eisai","pharmaFlowCategory":"D","therapeuticArea":"Otolaryngology (Ear, Nose, Throat)","country":"JAPAN","productType":"Small molecule","year":"2024","type":"Divestment","leadProduct":"Betahistine Dimesilate","moa":"","graph1":"Otolaryngology (Ear, Nose, Throat)","graph2":"Approved","graph3":"Kaken Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Otolaryngology","amount2New":0.029999999999999999,"dosageForm":"Tablet","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"},{"orgOrder":0,"company":"Kaken Pharmaceuticals","sponsor":"Numab Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Large molecule","year":"2024","type":"Collaboration","leadProduct":"ND081","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kaken Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Kaken Pharmaceuticals \/ Kaken Pharmaceuticals"}]

    Find Clinical Drug Pipeline Developments & Deals by Kaken Pharmaceuticals

    Menu

    Kaken Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ND081

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Recipient : Numab Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Numab and Kaken Collaborate On ND081 for Inflammatory Bowel Disease

                            Details : The collaboration aims to develop ND081, a potential first-in-class multi-specific antibody for the treatment of inflammatory bowel disease (IBD).

                            Brand Name : ND081

                            Molecule Type : Large molecule

                            Upfront Cash : $14.6 million

                            November 15, 2024

                            Lead Product(s) : ND081

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Recipient : Numab Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Betahistine Dimesilate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Study Phase : Approved

                            Recipient : Eisai

                            Deal Size : $25.0 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Eisai to Divest Rights for Merislon and Myonal in Japan to Kaken Pharmaceutical

                            Details : Eisai divested its rights for Merislon (betahistine mesilate), used to treat Meniere's syndrome, and muscle relaxant Myonal (eperisone hydrochloride) in Japan to Kaken.

                            Brand Name : Merislon

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 29, 2024

                            Lead Product(s) : Betahistine Dimesilate

                            Therapeutic Area : Otolaryngology (Ear, Nose, Throat)

                            Highest Development Status : Approved

                            Recipient : Eisai

                            Deal Size : $25.0 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NM26-2198

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I

                            Recipient : Numab Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Numab Therapeutics Announces First Subject Dosed in Phase 1 Clinical Study of NM26 Program

                            Details : NM26-2198 is a bi-specific antibody which targets IL-4Rα (type I and type II receptors) and IL-31 for the treatment of moderate-to-severe atopic dermatitis (AD).

                            Brand Name : NM26-2198

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 15, 2023

                            Lead Product(s) : NM26-2198

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I

                            Recipient : Numab Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Recipient : bitBiome

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            bitBiome and Kaken Pharmaceuticals Sign Joint Research Agreement on The Discovery of Drugs for Infectious Dise...

                            Details : Under the agreement, the companies will utilize the microbial platform technology developed by bitBiome to obtain drug candidates for the treatment of infectious diseases with high unmet medical needs.

                            Brand Name : Undisclosed

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 29, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Recipient : bitBiome

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Seladelpar Lysine

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Study Phase : Phase III

                            Recipient : CymaBay Therapeutics

                            Deal Size : $162.4 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            CymaBay Therapeutics Announces Collaboration with Kaken Pharmaceutical Co., Ltd. to Develop and Commercialize ...

                            Details : Under the terms of the agreement, Kaken receives an exclusive license to develop, commercialize and market MBX-8025 (seladelpar), a first-in-class treatment for people with primary biliary cholangitis (PBC), in Japan for PBC.

                            Brand Name : MBX-8025

                            Molecule Type : Small molecule

                            Upfront Cash : $34.0 million

                            January 08, 2023

                            Lead Product(s) : Seladelpar Lysine

                            Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)

                            Highest Development Status : Phase III

                            Recipient : CymaBay Therapeutics

                            Deal Size : $162.4 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase II

                            Recipient : Spruce Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement t...

                            Details : SPR001 (tildacerfont) is a potent and highly selective, non-steroidal, oral antagonist of the corticotropin-releasing factor (CRF) 1 receptor. The CRF1 receptor is abundantly expressed in the pituitary gland where it is the primary regulator of the HPA a...

                            Brand Name : SPR001

                            Molecule Type : Small molecule

                            Upfront Cash : $15.0 million

                            January 05, 2023

                            Lead Product(s) : Tildacerfont

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase II

                            Recipient : Spruce Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NM26-2198

                            Therapeutic Area : Dermatology

                            Study Phase : IND Enabling

                            Recipient : Numab Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Numab Therapeutics and Kaken Pharmaceutical Form Co-Development Alliance for a Next-Generation Atopic Dermatit...

                            Details : Under the expanded agreement, Kaken receives commercial rights for NM26-2198 in Japan, China, South Korea, Taiwan, Singapore, and Hong Kong, while Numab retains the commercial rights to the US, Europe, and the rest of the world.

                            Brand Name : NM26-2198

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 13, 2021

                            Lead Product(s) : NM26-2198

                            Therapeutic Area : Dermatology

                            Highest Development Status : IND Enabling

                            Recipient : Numab Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sofpironium Bromide

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Fresh Tracks Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary ...

                            Details : Sofpironium bromide gel was deemed to be safe and well tolerated in this study, as well as in the accompanying 52-week long-term safety extension study in Japan. Japan is the first country to approve sofpironium bromide with commercial launch expected la...

                            Brand Name : Ecclock

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 25, 2020

                            Lead Product(s) : Sofpironium Bromide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Fresh Tracks Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Kaken Pharmaceuticals

                            Japan arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sofpironium Bromide

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Recipient : Fresh Tracks Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Brickell Biotech Announces Issuance of New Composition of Matter Patent on Sofpironium Bromide by the Japanese...

                            Details : Brickell and Kaken Pharmaceutical were granted by the Japanese Patent Office a composition of matter patent with claims directed to the novel polymorphic, or crystalline, forms of sofpironium bromide, a retrometabolically designed new chemical entity.

                            Brand Name : BBI-4000

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 31, 2020

                            Lead Product(s) : Sofpironium Bromide

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Recipient : Fresh Tracks Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth